Stop-reason hub
OTHER/UNKNOWN clinical trial stops
Search 9,534 stopped clinical trials classified as other/unknown, with source-linked records and failure-signal context.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 0 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 9,534
Notable sponsors
- National Cancer Institute (NCI)
- 181
- M.D. Anderson Cancer Center
- 172
- Merck Sharp & Dohme LLC
- 164
- Novartis Pharmaceuticals
- 150
- GlaxoSmithKline
- 145
Related phases
- Phase II
- 3,175
- Phase I
- 2,900
- Phase III
- 1,342
- Phase IV
- 1,104
- Unknown
- 763
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase III Anatomic Stage 0 Breast Cancer AJCC v8 trial by Alliance for Clinical Trials in Oncology. Stop reason: OTHER/UNKNOWN.
Amending protocol to increase sample size
Phase II Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol
Phase II Lung Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol
Phase II Diffuse Large B-Cell Lymphoma trial by Genmab. Stop reason: OTHER/UNKNOWN.
The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety.
Phase III Eyelid Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Other
Phase II Glioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Study on hold pending possible updates with the team.
Phase IV Liver Transplant Failure and Rejection trial by University of Wisconsin, Madison. Stop reason: OTHER/UNKNOWN.
Resources
Phase II Alzheimer Disease trial by Merck Sharp & Dohme LLC. Stop reason: OTHER/UNKNOWN.
Termination Notes: Business reason
Phase III Hyperphagia trial by Aardvark Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Due to operational and regulatory considerations.
Phase II Hodgkin Lymphoma trial by Ranjana Advani. Stop reason: OTHER/UNKNOWN.
Discontinuation of magrolimab development
Phase III Hyperphagia trial by Aardvark Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Due to operational and regulatory considerations.
Phase II Non-Small Cell Lung Cancer (NSCLC) trial by University Health Network, Toronto. Stop reason: OTHER/UNKNOWN.
Study Terminated Prior to trial activation, due to changes in SOC of the treatment
Phase I Diastolic Dysfunction trial by Texas Tech University Health Sciences Center. Stop reason: OTHER/UNKNOWN.
Had issue enrolling subjects.
Phase I Metastatic Castration-resistant Prostate Cancer trial by University of Utah. Stop reason: OTHER/UNKNOWN.
DSMC Safety Analysis
Phase I Pain trial by University of Utah. Stop reason: OTHER/UNKNOWN.
Study is paused while preparing for implementation at IND Sponsor's new institution
Phase I Solid Tumor, Adult trial by Virginia Commonwealth University. Stop reason: OTHER/UNKNOWN.
Pending amendment approval
Phase I Glioblastoma Multiforme of Brain trial by Chimeric Therapeutics. Stop reason: OTHER/UNKNOWN.
IND application withdrawn
Phase III Acquired Factor X Deficiency trial by Kedrion S.p.A.. Stop reason: OTHER/UNKNOWN.
Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis.
Phase II Frailty trial by University of Rochester. Stop reason: OTHER/UNKNOWN.
The study has been suspended by the IRB pending review of a study-related issue
Phase I Lymphoma, Non-Hodgkin trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Acute Myeloid Leukemia trial by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Stop reason: OTHER/UNKNOWN.
Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML
Phase II Liver and Intrahepatic Bile Duct Carcinoma trial by OHSU Knight Cancer Institute. Stop reason: OTHER/UNKNOWN.
change in standard-of-care systemic therapy
Phase I Cutaneous Squamous Cell Carcinoma (CSCC) trial by Ankyra Therapeutics, Inc. Stop reason: OTHER/UNKNOWN.
Strategic realignment
Phase I Anatomic Stage III Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - DLT assessment and phase 2 dose determination
Phase III Soft Tissue Sarcoma trial by Polaris Group. Stop reason: OTHER/UNKNOWN.
Lack of Efficacy, no safety concern.
Phase II Advanced Head and Neck Squamous Cell Carcinoma trial by NRG Oncology. Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis
Phase III Agitation in Patients With Dementia of the Alzheimer's Type trial by Axsome Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Study AXS-05-AD-305 was terminated due to completion of overall program objectives.
Phase II Renal Angiomyolipomas trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of subject not reached
Phase III NSCLC trial by Spectrum Pharmaceuticals, Inc. Stop reason: OTHER/UNKNOWN.
The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
Unknown Sialorrhea True Bulbar Palsy Medullary Injury trial by houyajing. Stop reason: OTHER/UNKNOWN.
In accordance with the time-limit regulations for ethical review, since the ethical approval certificate of this study protocol has expired, I hereby formally apply for the withdrawal of this study from the clinical trial registration platform.
Phase I Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia trial by Nantes University Hospital. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Endometrial Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Revisions to ICF
Phase IV Valvular Heart Surgery trial by SHI Jia. Stop reason: OTHER/UNKNOWN.
At a meeting on February 17, 2025, the Data and Safety Monitoring Board recommended early termination because the predefined efficacy boundary was crossed.
Phase I Multiple Sclerosis (MS) trial by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Stop reason: OTHER/UNKNOWN.
Legend discontinues the development of the IMP.
Phase III Hereditary Hemorrhagic Telangiectasia trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of subject not reached
Phase I Lung Cancer trial by Shenzhen Geno-Immune Medical Institute. Stop reason: OTHER/UNKNOWN.
combine with NCT03356808
Phase II Covid19 trial by PureTech. Stop reason: OTHER/UNKNOWN.
Part A of the study was completed; Part B of the study was terminated
Phase II Prostate Cancer trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of patients not reached
Phase I GBA1 Parkinson Disease trial by Capsida Biotherapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.
Phase III Hemodynamic Instability trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
stop due to medication error with the placebo
Phase III Aortic Valve Stenosis trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of subjects not reached
Phase II Cystic Fibrosis trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
Target number of inclusion not reached
Phase III Sickle Cell Crisis trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
Target number of inclusion not reached
Phase I Advanced Hepatocellular Carcinoma trial by Roswell Park Cancer Institute. Stop reason: OTHER/UNKNOWN.
awaiting agreement with Sponsor
Unknown Prostate Cancer trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.
Flaw in the analytical technique
Phase I Head and Neck Cancer trial by Case Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.
PI leaving the institution
Phase I Cerebral Adrenoleukodystrophy trial by Masonic Cancer Center, University of Minnesota. Stop reason: OTHER/UNKNOWN.
Awaiting supplies
Unknown Healthy trial by Centre Hospitalier Universitaire de Nīmes. Stop reason: OTHER/UNKNOWN.
20131209 Regulatory authorization is currently blocked at the ANSM.
Phase III Delayed Graft Function trial by Apellis Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Study temporarily suspended due to company acquisition and ongoing strategic evaluation of the program
Phase II Membranous Nephropathy trial by Centre Hospitalier Universitaire de Nice. Stop reason: OTHER/UNKNOWN.
Only screenfail during inclusion period
Phase I Cancer trial by Biond Biologics. Stop reason: OTHER/UNKNOWN.
Study terminated due to strategic considerations
Phase I HER2-positive Breast Cancer trial by H. Lee Moffitt Cancer Center and Research Institute. Stop reason: OTHER/UNKNOWN.
Wait for the DLT period with our current patient and will not be enrolling any more.
Phase I HER2-positive Breast Cancer trial by Day One Biopharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Development discontinued.
Phase I SCLC trial by Y-mAbs Therapeutics. Stop reason: OTHER/UNKNOWN.
Decision by Sponsor
Phase I Metastatic Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Correlative sample analysis.
Unknown Moderate to Severe Ulcerative Colitis trial by University Hospital, Clermont-Ferrand. Stop reason: OTHER/UNKNOWN.
We were able to test our hypothesis using the current data
Phase II Hidradenitis Suppurativa (HS) trial by Boehringer Ingelheim. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Fatigue Syndrome trial by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Stop reason: OTHER/UNKNOWN.
occurrence of scientific risk
Phase I Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Amendment needed to add new dose level.
Phase IV Cesarean Section trial by Centre Hospitalier Universitaire de Nīmes. Stop reason: OTHER/UNKNOWN.
No inclusions.
Phase III Melanoma trial by Centre Hospitalier Universitaire de Nice. Stop reason: OTHER/UNKNOWN.
Rupture du traitement
Phase II Locally Recurrent Skin Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - safety run-in for initial cohort of participants
Phase III Non-small Cell Lung Cancer trial by Novartis Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Results of primary analysis showed addition of canakinumab to combination treatment did not improve tumor response or overall survival; the decision to stop the trial was not due to safety concerns
Phase I Metastatic Colorectal Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Pending amendment.
Phase I Relapsed/Refractory Multiple Myeloma trial by Second Affiliated Hospital of Xi'an Jiaotong University. Stop reason: OTHER/UNKNOWN.
Achieved the proof of concept
Phase I Relapsed/Refractory Autoimmune Diseases trial by Nanjing Legend Biotech Co.. Stop reason: OTHER/UNKNOWN.
pipeline adjustment
Phase II Colorectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
New information received
Phase III COVID-19 trial by University Hospital, Tours. Stop reason: OTHER/UNKNOWN.
COMPETITOR TEST (RECOVERY)
Phase II Metastatic Nasopharyngeal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Scheduled Interim Monitoring
Phase I Cutaneous T Cell Lymphoma trial by University of Alabama at Birmingham. Stop reason: OTHER/UNKNOWN.
IRB audit
Phase II Myocardial Infarction, Acute trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.
Inclusion period completed
Phase IV Aortic Stenosis, Non-rheumatic trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.
Difficulty of inclusion
Phase II Alcohol Use Disorder trial by Hôpital le Vinatier. Stop reason: OTHER/UNKNOWN.
Péremption des unités de traitement prévue début juin 2026. Compte tenu des délais de traitement, aucune administration ne sera plus possible après le 1 février 2026. Ces facteurs ne permettent plus de garantir la poursuite des inclusions.
Phase III Impulse Control Disorder trial by Centre Hospitalier Universitaire, Amiens. Stop reason: OTHER/UNKNOWN.
Zambon corparate has decided not to renew the production of the samples.
Phase I Advanced Solid Tumors trial by Vividion Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
The study has ended
Phase II Soft Tissue Sarcoma trial by Sun Yat-sen University. Stop reason: OTHER/UNKNOWN.
The study was terminated due to initiation of a new clinical trial with an updated study design.
Phase I Diabetes Mellitus, Type 2 trial by McMaster University. Stop reason: OTHER/UNKNOWN.
Withdrawn
Phase I Advanced Solid Tumor trial by SpringWorks Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib
Phase II Estrogen Receptor Positive Breast Cancer trial by University of Pennsylvania. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Acute Myeloid Leukemia trial by Northwestern University. Stop reason: OTHER/UNKNOWN.
Premature withdrawal of investigational product per study sponsor.
Phase II Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Scheduled Interim Monitoring
Phase I Multiple Myeloma trial by Thomas Martin, MD. Stop reason: OTHER/UNKNOWN.
Safety Review
Phase I Glioblastoma Multiforme trial by Genenta Science. Stop reason: OTHER/UNKNOWN.
LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.
Phase III Influenza trial by BioCryst Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Locally Advanced Basal Cell Carcinoma trial by Thomas Jefferson University. Stop reason: OTHER/UNKNOWN.
Investigational product is not currently available to the study site.
Phase I Advanced Solid Tumors trial by Astellas Pharma Global Development, Inc.. Stop reason: OTHER/UNKNOWN.
Lack of clinical benefit
Phase II MAC Lung Disease trial by AN2 Therapeutics, Inc. Stop reason: OTHER/UNKNOWN.
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.
Phase I Developmental and Epileptic Encephalopathy trial by Capsida Biotherapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Stopping rule for study was met
Phase III Sleep Apnea trial by University Hospital, Limoges. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Thrombotic Microangiopathies trial by University Hospital, Rouen. Stop reason: OTHER/UNKNOWN.
Change in the molecule
Phase III Dravet Syndrome (DS) trial by Takeda. Stop reason: OTHER/UNKNOWN.
Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study
Phase I Periorbital Burns trial by Virginia Commonwealth University. Stop reason: OTHER/UNKNOWN.
Inventory not available
Phase III Pain Due to Certain Specified Procedures trial by University Hospital, Limoges. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Pulmonary Arterial Hypertension trial by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Stop reason: OTHER/UNKNOWN.
Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies.
Unknown Dental Anxiety trial by University Hospital, Strasbourg, France. Stop reason: OTHER/UNKNOWN.
inclusion challenges
Phase II Aplastic Anemia trial by Peking Union Medical College Hospital. Stop reason: OTHER/UNKNOWN.
The ethical application for the institution was not completed, and the research was not carried out.
Phase II Mesothelioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
On hold pending updates to the drug/manufacturer information.
Phase II Lymphoma, B-Cell trial by The First Affiliated Hospital of Soochow University. Stop reason: OTHER/UNKNOWN.
The study was terminated due to changes in national policy.
Phase II Analgesia trial by Arthritis Innovation Corporation. Stop reason: OTHER/UNKNOWN.
Study superseded by alternative Phase 3 trial
Phase I Ovarian Cancer Recurrent trial by University of Alabama at Birmingham. Stop reason: OTHER/UNKNOWN.
never opened